Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Initiates global Phase 3 trial of BGB-3111 compared to bendamustine and rituximab (BR) in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patientsInitiates global...
-
CAMBRIDGE, Mass. and BEIJING, China, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
CAMBRIDGE, Mass. and BEIJING, China, Sept. 28, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
美国麻省剑桥和中国北京, Sept. 28, 2017 (GLOBE NEWSWIRE) --...
-
美国马萨诸塞州剑桥 和中国北京, Sept. 21, 2017 (GLOBE NEWSWIRE) -- 百济神州（纳斯达克代码：BGNE）是一家处于商业阶段的生物医药公司，专注于用于癌症治疗的创新型...
-
CAMBRIDGE, Mass. and BEIJING, China, Sept. 21, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
CAMBRIDGE, Mass. and BEIJING, China, Sept. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
-
美国马萨诸塞州剑桥和中国北京, Sept. 01, 2017 (GLOBE NEWSWIRE) -- 百济神州（纳斯达克代码：BGNE）是一家处于临床阶段的生物医药公司，专注于开发用于癌症治疗的创新型分子靶向和肿瘤免疫药物。公司今日完成与新基公司的肿瘤领域全球战略性合作相关交易。 ...